University of Münster
CRIS@UM
DE | EN

Dr. Martin Kropff

No current affiliations available for this person. The person is no longer active at the university.

Publications

POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience.
Thoennissen GB, Thoennissen NH, Fritz F, Hilbig A, Kerkhoff A, Liersch R, Krug U, Koschmieder S, Müller-Tidow C, Mesters R, Kropff M, Berdel WE (2012)
In: Annals of Hematology, 91(9), 1419-1425.
Research article (journal) | Published
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF (2011)
In: European Journal of Haematology, 86(1), 23-31.
Research article (journal) | Published
Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A (2011)
In: Cancer Treatment Reviews, 37(4), 266-283.
Research article (journal) | Published
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
Palumbo A, Davies F, Kropff M, Bladé J, Delforge M, Leal da Costa F, Garcia Sanz R, Schey S, Facon T, Morgan G, Moreau P (2010)
In: Annals of Hematology, 89(8), 803-911.
Research article (journal) | Published
Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.
Moehler TM, Feneberg R, Ho AD, Golenkov AK, Ludwig H, Kropff M, Khuageva NK, Hajda J, von Broen I, Goldschmidt H (2010)
In: Anti-Cancer Drugs, 21(7), 708-715.
Research article (journal) | Published
Show all publications